Corrigendum: Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy [Ann Oncol, 28, Suppl 12, (2017)] DOI:10.1093/annonc/mdx237;Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy

Annals of Oncology

Volumn 28, Issue , 2017, Pages xii44-xii55

  Sanchez Paulete A R ^a   Teijeira, A ^a   Cueto, F J ^b,c   Garasa, S ^a   Perez Gracia J L ^d,e   Sanchez Arraez A ^a   Sancho, D ^b   Melero, Ignacio ^a,d,e  

^a UNIVERSITY OF NAVARRA   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e Autonomous University of Madrid Instituto de Investigación Hospital Universitario La Paz   (Spain)

Author keywords

Cancer immunotherapy; Cross presentation; Cross priming; Dendritic cells; T cells

Indexed keywords

ANTHRACYCLINE; BETA CATENIN; CD134 ANTIGEN; CD137 LIGAND; CD70 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KRUPPEL LIKE FACTOR 4; MITOXANTRONE; NOTCH2 RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR ANTIGEN;

CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOPLASMIC RETICULUM; ENDOSOME; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; IONIZING RADIATION; LANGERHANS CELL; LYMPH VESSEL; MALIGNANT NEOPLASM; NONHUMAN; ONTOGENY; PHAGOCYTOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TRANSCRIPTOMICS; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; ANTIGEN PRESENTATION; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CROSS-PRIMING; DENDRITIC CELLS; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 85039552232     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx727     Document Type: Erratum

References (198)

1. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976; 143: 1283-1288
2. Belz GT, Behrens GM, Smith CM et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002; 196: 1099-1104
3. Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci U S A 1978; 75: 5132-5136
4. Hildner K, Edelson BT, Purtha WE et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008; 322: 1097-1100
5. Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev 2010; 234: 18-31
6. Poulin LF, Salio M, Griessinger E et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207: 1261-1271
7. Crozat K, Guiton R, Contreras V et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207: 1283-1292
8. Bachem A, Guttler S, Hartung E et al. Superior antigen crosspresentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207: 1273-1281
9. Jongbloed SL, Kassianos AJ, McDonald KJ et al. Human CD141+(BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207: 1247-1260
10. Crozat K, Guiton R, Guilliams M et al. Comparative genomics as a tool to reveal functional equivalences between human and mouse dendritic cell subsets. Immunol Rev 2010; 234: 177-198
11. Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med 2013; 210: 1035-1047
12. Bol KF, Schreibelt G, Gerritsen WR et al. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res 2016; 22: 1897-1906
13. Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016; 6: 71-79
14. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137: 1142-1162
15. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996; 183: 283-287
16. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995; 1: 1297-1302
17. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517-1526
18. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995; 182: 255-260
19. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24: 605-610
20. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15: 94-103
21. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277
22. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30: 1-22
23. Schraml BU, Reise Sousa C. Defining dendritic cells. Curr Opin Immunol 2015; 32: 13-20
24. Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13: 1145-1154
25. Guilliams M, Ginhoux F, Jakubzick C et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol 2014; 14: 571-578
26. Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 2011; 35: 323-335
27. Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009; 10: 1237-1244
28. Miller JC, Brown BD, Shay T et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol 2012; 13: 888-899
29. Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev 2010; 234: 5-17
30. Merad M, Sathe P, Helft J et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31: 563-604
31. Murphy TL, Grajales-Reyes GE, Wu X et al. Transcriptional control of dendritic cell development. Annu Rev Immunol 2016; 34: 93-119
32. Mayer CT, Ghorbani P, Nandan A et al. Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 2014; 124: 3081-3091
33. Helft J, Bottcher J, Chakravarty P et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity 2015; 42: 1197-1211
34. Dubsky P, Saito H, Leogier M et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 2007; 37: 1678-1690
35. Le Bon A, Etchart N, Rossmann C et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-1015
36. Tel J, Schreibelt G, Sittig SP et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2013; 121: 459-467
37. Stoitzner P, Tripp CH, Eberhart A et al. Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci U S A 2006; 103: 7783-7788
38. Klechevsky E, Morita R, Liu M et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29: 497-510
39. van der Vlist M, Geijtenbeek TB. Langerin functions as an antiviral receptor on Langerhans cells. Immunol Cell Biol 2010; 88: 410-415
40. Tussiwand R, Everts B, Grajales-Reyes GE et al. Klf4 expression in conventional dendritic cells is required for T helper 2 cell responses. Immunity 2015; 42: 916-928
41. Schlitzer A, McGovern N, Teo P et al. IRF4 transcription factordependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013; 38: 970-983
42. Persson EK, Uronen-Hansson H, Semmrich M et al. IRF4 transcriptionfactor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation. Immunity 2013; 38: 958-969
43. Plantinga M, Guilliams M, Vanheerswynghels M et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity 2013; 38: 322-335
44. Seillet C, Jackson JT, Markey KA et al. CD8alpha+ DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3. Blood 2013; 121: 1574-1583
45. Schlitzer A, Sivakamasundari V, Chen J et al. Identification of cDC1-and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nat Immunol 2015; 16: 718-728
46. Breton G, Zheng S, Valieris R et al. Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs. J Exp Med 2016; 213: 2861-2870
47. Grajales-Reyes GE, Iwata A, Albring J et al. Batf3 maintains autoactivation of Irf8 for commitment of a CD8alpha(+) conventional DC clonogenic progenitor. Nat Immunol 2015; 16: 708-717
48. Edelson BT, Kc W, Juang R et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J Exp Med 2010; 207: 823-836
49. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12: 557-569
50. Segura E, Amigorena S. Cross-Presentation in Mouse and Human Dendritic Cells. Adv Immunol 2015; 127: 1-31
51. Ruffell B, Chang-Strachan D, Chan V et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014; 26: 623-637
52. Mashayekhi M, Sandau MM, Dunay IR et al. CD8alpha(+) dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites. Immunity 2011; 35: 249-259
53. Martinez-Lopez M, Iborra S, Conde-Garrosa R, Sancho D. Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice. Eur J Immunol 2015; 45: 119-129
54. Iborra S, Martinez-Lopez M, Khouili SC et al. Optimal generation of tissue-resident but not circulating memory T cells during viral infection requires crosspriming by DNGR-1+ dendritic cells. Immunity 2016; 45: 847-860
55. Iborra S, Izquierdo HM, Martinez-Lopez M et al. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J Clin Invest. 2012; 122: 1628-1643
56. Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016; 37: 855-865
57. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015; 523: 231-235
58. Broz ML, Binnewies M, Boldajipour B et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014; 26: 638-652
59. Spranger S, Luke JJ, Bao R et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A 2016; 113: E7759-E7768
60. Roberts EW, Broz ML, Binnewies M et al. Critical role for CD103(+)/ CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016; 30: 324-336
61. Tel J, Aarntzen EH, Baba T et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73: 1063-1075
62. Bakdash G, Buschow SI, Gorris MA et al. Expansion of a BDCA1+CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines. Cancer Res 2016; 76: 4332-4346
63. Wimmers F, Schreibelt G, Skold AE et al. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 2014; 5: 165
64. Zehner M, Marschall AL, Bos E et al. The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for crosspresentation to CD8(+) T cells. Immunity 2015; 42: 850-863
65. Morel S, Levy F, Burlet-Schiltz O et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000; 12: 107-117
66. de Verteuil DA, Rouette A, Hardy MP et al. Immunoproteasomes shape the transcriptome and regulate the function of dendritic cells. J Immunol. 2014; 193: 1121-1132
67. Burgdorf S, Scholz C, Kautz A et al. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol. 2008; 9: 558-566
68. Firat E, Saveanu L, Aichele P et al. The role of endoplasmic reticulumassociated aminopeptidase 1 in immunity to infection and in crosspresentation. J Immunol.2007; 178: 2241-2248
69. Saveanu L, Carroll O, Weimershaus M et al. IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science 2009; 325: 213-217
70. Lin ML, Zhan Y, Proietto AI et al. Selective suicide of cross-presenting CD8+ dendritic cells by cytochrome c injection shows functional heterogeneity within this subset. Proc Natl Acad Sci U S A 2008; 105: 3029-3034
71. Shen L, Sigal LJ, Boes M, Rock KL. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 2004; 21: 155-165
72. Savina A, Jancic C, Hugues S et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006; 126: 205-218
73. Jancic C, Savina A, Wasmeier C et al. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol. 2007; 9: 367-378
74. Savina A, Peres A, Cebrian I et al. The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8(+) dendritic cells. Immunity 2009; 30: 544-555
75. Cebrian I, Visentin G, Blanchard N et al. Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells. Cell 2011; 147: 1355-1368
76. Schulz O, Reise Sousa C. Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology 2002; 107: 183-189
77. Iyoda T, Shimoyama S, Liu K et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002; 195: 1289-1302
78. Desch AN, Randolph GJ, Murphy K et al. CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med 2011; 208: 1789-1797
79. Headley MB, Bins A, Nip A et al. Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature 2016; 531: 513-517
80. Alfaro C, Suarez N, Onate C et al. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes. PLoS One.2011; 6: e29300
81. Schnorrer P, Behrens GM, Wilson NS et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A 2006; 103: 10729-10734
82. Dudziak D, Kamphorst AO, Heidkamp GF et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315: 107-111
83. Sancho D, Joffre OP, Keller AM et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009; 458: 899-903
84. Sancho D, Mourao-Sa D, Joffre OP et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008; 118: 2098-2110
85. Poulin LF, Reyal Y, Uronen-Hansson H et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 2012; 119: 6052-6062
86. Ahrens S, Zelenay S, Sancho D et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012; 36: 635-645
87. Zhang JG, Czabotar PE, Policheni AN et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity 2012; 36: 646-657
88. Salmon H, Idoyaga J, Rahman A et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 2016; 44: 924-938
89. Laoui D, Keirsse J, Morias Y et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Comms 2016; 7: 13720
90. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010; 207: 1791-1804
91. Ma Y, Adjemian S, Mattarollo SR et al. Anticancer chemotherapyinduced intratumoral recruitment and differentiation of antigenpresenting cells. Immunity 2013; 38: 729-741
92. McDonnell AM, Lesterhuis WJ, Khong A et al. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol 2015; 45: 49-59
93. Engelhardt JJ, Boldajipour B, Beemiller P et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 2012; 21: 402-417
94. Hirosue S, Vokali E, Raghavan VR et al. Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells. J Immunol 2014; 192: 5002-5011
95. Zong J, Keskinov AA, Shurin GV, Shurin MR. Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother 2016; 65: 821-833
96. Huarte E, Tirapu I, Arina A et al. Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin Biol Ther 2005; 5: 7-22
97. Jiang A, Bloom O, Ono S et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 2007; 27: 610-624
98. Manicassamy S, Reizis B, Ravindran R et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010; 329: 849-853
99. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell 2017; 31: 711-723 e714
100. Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J ExpMed 2005; 202: 919-929
101. Oderup C, LaJevic M, Butcher EC. Canonical and noncanonical Wnt proteins program dendritic cell responses for tolerance. J Immunol 2013; 190: 6126-6134
102. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007; 7: 817-823
103. Holtzhausen A, Zhao F, Evans KS et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res 2015; 3: 1082-1095
104. Chang CH, Qiu J, O'Sullivan D et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015; 162: 1229-1241
105. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013; 34: 137-143
106. Jantsch J, Chakravortty D, Turza N et al. Hypoxia and hypoxiainducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol 2008; 180: 4697-4705
107. Yang M, Ma C, Liu S et al. Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology.2009; 128: e237-e249
108. Yang M, Ma C, Liu S et al. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol Cell Biol 2010; 88: 165-171
109. Labiano S, Palazon A, Melero I. Immune response regulation in the tumor microenvironment by hypoxia. Semin Oncol 2015; 42: 378-386
110. Everts B, Amiel E, Huang SC et al. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKvarepsilon supports the anabolic demands of dendritic cell activation. Nat Immunol 2014; 15: 323-332
111. Ho PC, Bihuniak JD, Macintyre AN et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 2015; 162: 1217-1228
112. Brand A, Singer K, Koehl GE et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 2016; 24: 657-671
113. Nasi A, Fekete T, Krishnamurthy A et al. Dendritic cell reprogramming by endogenously produced lactic acid. J Immunol 2013; 191: 3090-3099
114. Ramakrishnan R, Tyurin VA, Veglia F et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol 2014; 192: 2920-2931
115. Herber DL, Cao W, Nefedova Y et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 2010; 16: 880-886
116. Cubillos-Ruiz JR, Silberman PC, Rutkowski MR et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 2015; 161: 1527-1538
117. Bougneres L, Helft J, Tiwari S et al. A role for lipid bodies in the crosspresentation of phagocytosed antigens by MHC class I in dendritic cells. Immunity 2009; 31: 232-244
118. Hong Y, Manoharan I, Suryawanshi A et al. Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. Oncoimmunology 2016; 5: e1115941
119. Raich-Regue D, Fabian KP, Watson AR et al. Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology 2016; 5: e1146841
120. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704
121. Hirano F, Kaneko K, Tamura H et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65: 1089-1096
122. Lim TS, Chew V, Sieow JL et al. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. Oncoimmunology 2016; 5: e1085146
123. Chiba S, Baghdadi M, Akiba H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012; 13: 832-842
124. Kim TS, Gorski SA, Hahn S et al. Distinct dendritic cell subsets dictate the fate decision between effector and memory CD8(+) T cell differentiation by a CD24-dependent mechanism. Immunity 2014; 40: 400-413
125. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1: 510-514
126. Sica A, Saccani A, Bottazzi B et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumorassociated macrophages. J Immunol 2000; 164: 762-767
127. Redondo P, del Olmo J, Lopez-Diaz de Cerio A et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol 2007; 127: 1673-1680
128. Aspord C, Tramcourt L, Leloup C et al. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization. J Invest Dermatol 2014; 134: 2551-2561
129. Aznar MA, Tinari N, Rullan AJ et al. Intratumoral delivery of immunotherapy-act locally, think globally. J Immunol 2017; 198: 31-39
130. Van Lint S, Renmans D, Broos K et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res 2016; 4: 146-156
131. Wilgenhof S, Van Nuffel AM, Benteyn D et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013; 24: 2686-2693
132. Wilgenhof S, Corthals J, Heirman C et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDCMEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 2016; 34: 1330-1338
133. Tirapu I, Arina A, Mazzolini G et al. Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer 2004; 110: 51-60
134. Mazzolini G, Alfaro C, Sangro B et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005; 23: 999-1010
135. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72
136. Galluzzi L, Buque A, Kepp O et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017; 17: 97-111
137. Kepp O, Senovilla L, Vitale I et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3: e955691
138. Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701
139. Elliott MR, Chekeni FB, Trampont PC et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-286
140. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61
141. Salimu J, Spary LK, Al-Taei S et al. Cross-presentation of the oncofetal tumor antigen 5T4 from irradiated prostate cancer cells-a key role for heat-shock protein 70 and receptor CD91. Cancer Immunol Res 2015; 3: 678-688
142. Albert ML, Pearce SF, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and crosspresent antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359-1368
143. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059
144. Ghiringhelli F, Apetoh L, Tesniere A et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178
145. Garg AD, Vandenberk L, Koks C et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med.2016; 8: 328ra327
146. Vandenberk L, Garg AD, Verschuere T et al. Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology 2016; 5: e1083669
147. Obeid M, Panaretakis T, Joza N et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14: 1848-1850
148. Fucikova J, Moserova I, Truxova I et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 2014; 135: 1165-1177
149. Gamrekelashvili J, Kapanadze T, Han M et al. Peptidases released by necrotic cells control CD8+ T cell cross-priming. J Clin Invest 2013; 123: 4755-4768
150. Yatim N, Jusforgues-Saklani H, Orozco S et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science 2015; 350: 328-334
151. Aaes TL, Kaczmarek A, Delvaeye T et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep 2016; 15: 274-287
152. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305
153. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004; 4: 469-478
154. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33: 35-41
155. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17: 275-281
156. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010; 28: 57-78
157. Sanmamed MF, Pastor F, Rodriguez A et al. Agonists of co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 2015; 42: 640-655
158. Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196: 1627-1638
159. Cohn L, Chatterjee B, Esselborn F et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med 2013; 210: 1049-1063
160. Huysamen C, Willment JA, Dennehy KM, Brown GD. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes. J Biol Chem 2008; 283: 16693-16701
161. Schraml BU, van Blijswijk J, Zelenay S et al. Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. Cell 2013; 154: 843-858
162. Zelenay S, Keller AM, Whitney PG et al. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J Clin Invest 2012; 122: 1615-1627
163. Sancho D, Reise Sousa C. Sensing of cell death by myeloid C-type lectin receptors. Curr Opin Immunol 2013; 25: 46-52
164. Yan Z, Wu Y, Du J et al. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy. Oncotarget 2016; 7: 40437-40450
165. Fossum E, Grodeland G, Terhorst D et al. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus. Eur J Immunol 2015; 45: 624-635
166. Carreno BM, Magrini V, Becker-Hapak M et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348: 803-808
167. Gubin MM, Zhang X, Schuster H et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515: 577-581
168. Kranz LM, Diken M, Haas H et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534: 396-401
169. Kreiter S, Selmi A, Diken M et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res.2010; 70: 9031-9040
170. Schiavoni G, Sistigu A, Valentini M et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res.2011; 71: 768-778
171. Tesniere A, Schlemmer F, Boige V et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491
172. Byrne KT, Vonderheide RH. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep. 2016; 15: 2719-2732
173. Sistigu A, Viaud S, Chaput N et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33: 369-383
174. Vatner RE, Cooper BT, Vanpouille-Box C et al. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014; 4: 325
175. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015; 15: 409-425
176. Sharabi AB, Nirschl CJ, Kochel CM et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res.2015; 3: 345-355
177. Kim KW, Kim SH, Shin JG et al. Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int J Cancer 2004; 109: 685-690
178. Teitz-Tennenbaum S, Li Q, Okuyama R et al. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother 2008; 31: 345-358
179. Deng L, Liang H, Xu M et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014; 41: 843-852
180. Rodriguez-Ruiz ME, Rodriguez I, Garasa S et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming. Cancer Res 2016; 76: 5994-6005
181. Dovedi SJ, Lipowska-Bhalla G, Beers SA et al. Antitumor efficacy of radiation plus immunotherapy depends upon dendritic cell activation of effector CD8+ T cells. Cancer Immunol Res 2016; 4: 621-630
182. Reynders K, Illidge T, Siva S et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015; 41: 503-510
183. Twyman-Saint Victor C, Rech AJ, Maity A et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520: 373-377
184. Ruocco MG, Pilones KA, Kawashima N et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest. 2012; 122: 3718-3730
185. Liao YP, Wang CC, Butterfield LH et al. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol. 2004; 173: 2462-2469
186. Klug F, Prakash H, Huber PE et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell.2013; 24: 589-602
187. Dewan MZ, Vanpouille-Box C, Kawashima N et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res 2012; 18: 6668-6678
188. Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28: 4324-4332
189. Adams S, Kozhaya L, Martiniuk F et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res 2012; 18: 6748-6757
190. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A et al. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011; 17: 2619-2627
191. Diamond MS, Kinder M, Matsushita H et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208: 1989-2003
192. Fuertes MB, Kacha AK, Kline J et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8(alpha)+ dendritic cells. J Exp Med 2011; 208: 2005-2016
193. Liu X, Pu Y, Cron K et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 2015; 21: 1209-1215
194. Barber GN. STING-dependent cytosolic DNA sensing pathways. Trends Immunol 2014; 35: 88-93
195. Corrales L, Glickman LH, McWhirter SM et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015; 11: 1018-1030
196. Woo SR, Fuertes MB, Corrales L et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41: 830-842
197. Arina A, Tirapu I, Alfaro C et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming. Exp. Hematol 2002; 30: 1355-1364
198. Melero I, Arina A, Murillo O et al. Immunogenic cell death and crosspriming are reaching the clinical immunotherapy arena. Clin Cancer Res 2006; 12: 2385-2389